- Home
- NML vs RLAY Comparison
NML vs RLAY Comparison
Compare NML & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NML | RLAY |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 497.5M | 1.3B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NML | RLAY |
|---|---|---|
| Price | $10.35 | $9.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.86 |
| AVG Volume (30 Days) | 177.8K | ★ 2.4M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 9.75% | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $324.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $7.10 | $1.78 |
| 52 Week High | $10.44 | $11.49 |
Technical Indicators
Market Signals| Indicator | NML | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 64.61 | 49.13 |
| Support Level | $8.35 | $9.06 |
| Resistance Level | $10.44 | $11.46 |
| Average True Range (ATR) | 0.17 | 0.61 |
| MACD | -0.02 | -0.14 |
| Stochastic Oscillator | 78.04 | 22.63 |
Price Performance
Historical ComparisonAbout NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States. Invest in Capital Markets, Chemicals, Oil, Gas & Consumable Fuels, Electric Utilities, Independent Power and Renewable Electricity Producers, Multi Utilities. Maximum is done in Oil, Gas & Consumable Fuels.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).